Teachers Retirement System of The State of Kentucky lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 37.7% during the first quarter, Holdings Channel reports. The firm owned 336,426 shares of the biopharmaceutical company’s stock after selling 203,891 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Gilead Sciences were worth $22,850,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Parnassus Investments CA boosted its position in Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its position in Gilead Sciences by 75.0% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after buying an additional 1,092,206 shares during the last quarter. AQR Capital Management LLC boosted its position in Gilead Sciences by 25.7% in the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after buying an additional 1,066,172 shares during the last quarter. Finally, Swiss National Bank boosted its position in Gilead Sciences by 26.9% in the first quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock valued at $317,059,000 after buying an additional 989,400 shares during the last quarter. Institutional investors and hedge funds own 74.02% of the company’s stock.

Gilead Sciences, Inc. (GILD) traded up 0.25% during trading on Tuesday, hitting $72.99. The stock had a trading volume of 1,356,361 shares. The firm’s 50 day moving average is $72.43 and its 200 day moving average is $68.75. The firm has a market cap of $95.32 billion, a price-to-earnings ratio of 7.93 and a beta of 1.21. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the previous year, the company posted $3.08 earnings per share. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.76 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.

ILLEGAL ACTIVITY WARNING: “Teachers Retirement System of The State of Kentucky Has $22.85 Million Stake in Gilead Sciences, Inc. (GILD)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/teachers-retirement-system-of-the-state-of-kentucky-has-22-85-million-stake-in-gilead-sciences-inc-gild/1491165.html.

Several research analysts have issued reports on GILD shares. Cowen and Company reiterated a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a research report on Monday, April 17th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 price objective for the company in a research report on Tuesday, April 18th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 21st. Piper Jaffray Companies reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, April 21st. Finally, Barclays PLC reiterated an “overweight” rating and issued a $85.00 price objective (down previously from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd. Twelve research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $80.31.

In other news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now owns 106,113 shares in the company, valued at approximately $8,051,854.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock worth $15,223,184 in the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.